ClinicalTrials.gg
RecruitingNCT06724562Updated Aug 6, 2026

IL1 Inhibition in FOP

An observational study in Fibrodysplasia Ossificans Progressiva (FOP), sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 6 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by University of California, San Francisco · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
11
Ages
6 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Myositis Ossificans with a site in United States — 4 open to participants now, 6 under way, 2 of them phase 3. Myositis Ossificans · United States.

Started
2025
the only one that year
Observational
7 of 19
3 open now
Registered
19th of 19
by date
Lead sponsor
1 of 19
University of California, San Francisco

Among the 19 studies in Myositis Ossificans with a site in United States, this one is the only one that started in 2025, is one of 7 observational ones, and was the 19th registered.

Myositis Ossificans

24 studies on the registry are indexed under Myositis Ossificans; 5 are open to participants now.

Browse Myositis Ossificans studies →

Open to participants now

4 of the 19 studies in Myositis Ossificans with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Myositis Ossificans studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 6 Years to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Myositis Ossificans with a site in United States, or all of them as a file.
02

Study summary

This is an observational pre-post study to observe if the off label use of anti-IL1 therapies, such as anakinra or canakinumab, can block ACVR1-induced flare activity and heterotopic ossification in FOP. It will also generate key tools and preliminary data that are needed to design a future Phase II study.

This study specifically focuses on patients with severe FOP who are being considered by their medical team for rescue therapy with anti-IL1 therapy. Preliminary data suggests patients experience significant decreases in flare frequency when taking anti-IL1 therapy, but other measures of efficacy remain unassessed, such as changes in heterotopic ossification formation, changes in pain medication use, and changes in functionality.

Read the detailed description

The investigators will perform an observational study on patients with FOP who have decided, along with their primary medical team, to start anti-IL1 therapy with either anakinra or canakinumab due to intractable or unusually severe FOP disease progression. The investigators will study 11 subjects aged 6-30 years old, with a self-reported flare frequency of at least 4 flares/year [2 times above the average reported FOP population flare frequency of 2 flares/year] or with an intractable flare that has lasted greater than 1 month. Subjects will begin an observational period during the medication prescription and insurance approval process and will then be followed for up to 1 year after treatment has been initiated by the medical management team. Low-dose whole-body CT (WBCT) imaging, bloodwork, patient-reported outcomes, pain, and flare activity will be assessed during this study. In addition, patients who are currently on anti-IL1 therapy, or are unable to attain anti-IL1 therapy, will be enrolled in a separate observation-only arm to collect historical data related to their experiences on therapy.

03

Conditions studied

  • Fibrodysplasia Ossificans Progressiva (FOP)

Keywords

  • heterotopic ossification
  • canakinumab
  • anakinra
  • FOP
04

Who can participate

Ages eligible
6 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects with a diagnosis of FOP who meet the inclusion and exclusion criteria will be eligible for participation in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a clinical presentation consistent with FOP and a genetic diagnosis of classical FOP (ACVR1R206H variant) (2), male or female aged 6-30 years old.
  • Patients with unusually severe FOP disease activity. This will be determined by FOP flare frequency of >4 flares per year, which is 2 times higher than the reported average in prior FOP studies ; or by a persistent flare that has failed to resolve after 1 month of standard-of-care therapy.
  • Patients whose primary medical team has decided that rescue therapy with an anti-IL1 medication should be initiated. Once the primary medical team has decided that anti-IL1 therapy should be pursued, the subject will be told about this clinical-observational study and enrolled in the pre-treatment phase while access to the anti-IL1 therapy is being obtained by the clinical management team.
  • Ability to participate in all assessments, including blood draws, radiology assessments, and travel. Age 6 is chosen as the lower limit to avoid the need for anesthesia for whole body CT in younger subjects.
  • No history of unexplained infections, known disease, or to anti-IL1 therapy.
  • Written (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  • Pregnant, breastfeeding, or unwilling to practice during participation in the study.
  • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
  • Inability to travel to site for assessments
  • Pre-existing or autoinflammatory disease (aside from FOP)
  • Inability to tolerate assessments (such as phlebotomy)
  • Unexplained infections
  • Current participation in an interventional trial, or study of a potentially disease modifying medication
  • Inability to take medications as prescribed by managing physician
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
11 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Anti-IL1 Observational Arm

    FOP patients that are beginning treatment with Anti-IL1 Therapy

    Other: Anti-IL1 Therapy

  • Optional Non-Treatment Observational Arm

    FOP patients unable to obtain Anti-IL1 therapy

  • "On Treatment" Observational Arm

    FOP patients that are already using Anti-IL1 therapy

Interventions

  • OtherAnti-IL1 Therapy

    Anti-IL1 is a rescue therapy for FOP patients that is hypothesized to reduce flare activity and subsequent ossification in these patients

    Also known as: Canakinumab, Anakinra

06

What researchers measure

Primary outcomes

  1. Number of flares that a patient experiences.

    Surveys will be used to track the number of clinical flares that a patient experiences before and during treatment with anti-IL1 therapy.

    Time frame: 1 year

Secondary outcomes

  1. Change in new heterotopic ossification bone formation over time

    Low dose whole body CT (WBCT) without the head, will be used to create detailed images of the skeletal system. The images will be used to measure new HO bone formation from baseline.

    Time frame: 1 year

  2. Changes in blood inflammatory cytokine levels with anti-IL1 therapy

    Blood samples will be taken to measure changes in the inflammatory cytokines present in the blood over time, and if this changes with anti-IL1 treatment.

    Time frame: 1 year

  3. Change in patient mobility

    The Cumulative Analog Joint Involvement Scale (CAJIS) will be used to assess 15 major joints for their mobility. This will be compared from baseline vs. 1 year of anti-IL1 treatment.

    Time frame: 1 year

  4. Number of participants with treatment emergent adverse events (TEAEs)

    The number of participants with adverse events (ie adverse events not at baseline) will be collected during the treatment period.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Haviv R, Zeitlin L, Moshe V, Ziv A, Rabinowicz N, De Benedetti F, Prencipe G, Matteo V, De Cunto CL, Hsiao EC, Uziel Y. Long-term use of interleukin-1 inhibitors reduce flare activity in patients with fibrodysplasia ossificans progressiva. Rheumatology (Oxford). 2024 Sep 1;63(9):2597-2604. doi: 10.1093/rheumatology/keae255. PubMed 38733591 ↗
  • Haviv R, Moshe V, De Benedetti F, Prencipe G, Rabinowicz N, Uziel Y. Is fibrodysplasia ossificans progressiva an interleukin-1 driven auto-inflammatory syndrome? Pediatr Rheumatol Online J. 2019 Dec 21;17(1):84. doi: 10.1186/s12969-019-0386-6. PubMed 31864380 ↗

Individual participant data

Plan to share: Yes — Patient data will be deidentified and shared following NIH policies for aggregate and individual level data.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Within 2 years of the end of the study.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Nov 2027, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2024
First posted
Dec 9, 2024
StartActual
Apr 1, 2025
Primary completionEst.
Nov 5, 2027
CompletionEst.
Nov 5, 2027
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06724562
Responsible party
Sponsor
First posted
Dec 9, 2024
Start date
Apr 1, 2025
Primary completion
Nov 5, 2027 (estimated)
Completion
Nov 5, 2027 (estimated)
Last update
Aug 6, 2026

Study contacts

Samantha Klein
Contact
Samantha.klein@ucsf.edu
415-254-5748
Judy Gonzalez-Vargas
Contact
Judy.Gonzalez-Vargas@ucsf.edu
415-254-5048
Edward Hsiao, MD, PhD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion